Genmab Discontinues Acasunlimab Development to Focus on Late-Stage Pipeline Programs
核心洞察
Genmab announced the discontinuation of acasunlimab clinical development following a strategic portfolio review to prioritize higher-impact opportunities.
The decision reflects the company's focus on late-stage programs including EPKINLY, petosemtamab, and rinatabart sesutecan amid an increasingly competitive landscape.
Despite encouraging clinical data for acasunlimab, Genmab will concentrate resources on programs with the highest potential impact for patients and shareholders.
Genmab A/S announced it will discontinue further clinical development of acasunlimab as part of a strategic portfolio review aimed at focusing resources on the most value-creating opportunities in its late-stage pipeline. The decision comes amid an evolving competitive landscape and reflects the company's disciplined approach to capital allocation.
Strategic Portfolio Prioritization
The biotechnology company will concentrate its efforts on three key late-stage programs: EPKINLY (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S), which are advancing in late-stage development. This strategic shift aligns with Genmab's portfolio prioritization and capital allocation framework designed to maximize impact for both patients and shareholders.
"After careful consideration, we have decided to discontinue the acasunlimab program. Although the data have been encouraging, the compelling opportunities we see in our late-stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Clinical Data and Competitive Landscape
While Genmab characterized the clinical profile observed for acasunlimab as "encouraging," the company determined that the increasingly competitive landscape warranted a strategic reallocation of resources. The decision represents a thorough assessment of where the company can achieve the highest potential impact across its development portfolio.
Van de Winkel emphasized the company's enthusiasm for its prioritized programs, stating, "We are highly energized by the momentum of EPKINLY, petosemtamab and Rina-S, and we remain committed to executing these programs with speed and rigor."
Financial Impact
The discontinuation of acasunlimab development is expected to have no impact on Genmab's full-year 2025 financial guidance. This decision is consistent with the company's established framework for portfolio management and capital allocation, designed to optimize resource deployment across its pipeline.
Company Background
Genmab is an international biotechnology company with over 25 years of experience in developing antibody medicines for cancer (搜索) and other serious diseases. The company has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), and immune-modulating antibodies. Genmab's science currently powers eight approved antibody medicines, and the company maintains a strong late-stage clinical pipeline focused on delivering transformative medicines to patients.